Calliditas Therapeutics

company

About

Calliditas Therapeutics is a specialty pharmaceutical company that develops pharmaceutical products in fields of unmet medical needs.

  • 51 - 100

Details

Last Funding Type
Debt Financing
Last Funding Money Raised
$75M
Industries
Biotechnology,Medical Device,Pharmaceutical
Founded date
Jan 1, 1991
Number Of Employee
51 - 100
Operating Status
Active

Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas is focused on the development and commercialization of the product candidate Nefecon, a unique two step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$75M
Calliditas Therapeutics has raised a total of $75M in funding over 2 rounds. Their latest funding was raised on Jul 15, 2021 from a Debt Financing round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 15, 2021 Debt Financing $75M 1 Kreos Capital Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Calliditas Therapeutics is funded by 1 investors. Kreos Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Kreos Capital Yes Debt Financing